Founded in 1996, Biotecnol started as a consultancy firm before transitioning to independent research and development activities. With headquarters in the UK and research facilities in Portugal, the company focuses on developing multifunctional antibodies for rare and aggressive cancer subtypes. Biotecnol has also established a subsidiary in the US and partnered with Cancer Research UK for clinical development. Their proprietary drug pipeline includes treatments for triple-negative breast cancer and malignant mesothelioma, utilizing the patient's own immune system to fight cancer.